IMPROVED SURVIVAL AFTER RADIOTHERAPY FOR BRAIN METASTASES IN PATIENTS WITH HER2 POSITIVE BREAST TUMORS
M Maur(University of Modena and Reggio Emilia), PierFranco Conte(University of Padua), Guido Ficarra(University of Modena and Reggio Emilia), D. Ramundo, Roberto Sabbatini(Azienda Ospedaliero-Universitaria di Modena), Falchi Am, Federica Bertolini, Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Simona Giovannelli(University of Modena and Reggio Emilia)
IRIS UNIMORE (University of Modena and Reggio Emilia)
January 1, 2005
Cited by 2
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879